Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.
Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.
Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.
Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.
Genfit announced results from an interim analysis of the RESOLVE-IT Phase III trial evaluating once-daily, 120mg of elafibranor in adults with non-alcoholic steatohepatitis (NASH). The trial did not… read more.
Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.
by Gary Finnegan: People seeking refuge and asylum in Germany are at higher risks of liver problems due to hepatitis B, according to experts.
Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.
Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.
Feature Symposium. Stephen Strom, Karolinska Institutet, Stockholm, Sweden. Luc van der Laan, Erasmus Medical Center, Rotterdam, the Netherlands. Alberto Sanchez-Fueyo, King’s College Hospital, London, UK. David Hay, University… read more.
Report from the Joint International Congress of ILTS, ELITA and LICAGE 2014. Recurrence of hepatitis C virus (HCV) infection after transplantation is a major challenge for centres all… read more.
Report from the Joint International Congress of ILTS, ELITA and LICAGE 2014. Roger Williams, Institute of Hepatology/Foundation for Liver Research, London, UK. Medical care after acute liver failure… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
